Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Operating Leases: 2022-2025

Historic Operating Leases for Taysha Gene Therapies (TSHA) over the last 3 years, with Sep 2025 value amounting to $16.5 million.

  • Taysha Gene Therapies' Operating Leases fell 7.01% to $16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year decrease of 7.01%. This contributed to the annual value of $17.4 million for FY2024, which is 8.40% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Operating Leases is $16.5 million, which was down 1.80% from $16.8 million recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Operating Leases high stood at $20.4 million for Q4 2022, and its period low was $16.5 million during Q3 2025.
  • Its 3-year average for Operating Leases is $18.2 million, with a median of $18.1 million in 2024.
  • Data for Taysha Gene Therapies' Operating Leases shows a maximum YoY declined of 8.40% (in 2024) over the last 5 years.
  • Over the past 4 years, Taysha Gene Therapies' Operating Leases (Quarterly) stood at $20.4 million in 2022, then fell by 7.27% to $19.0 million in 2023, then decreased by 8.40% to $17.4 million in 2024, then declined by 7.01% to $16.5 million in 2025.
  • Its last three reported values are $16.5 million in Q3 2025, $16.8 million for Q2 2025, and $17.1 million during Q1 2025.